At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LMNL Liminal BioSciences Inc.
Post-Market Trading 11-22 18:03:29 EST
8.50
+0.00
0.00%
High8.50
Low8.50
Vol0.00
Open8.50
D1 Closing8.50
Amplitude0.00%
Mkt Cap27.62M
Tradable Cap10.69M
Total Shares3.25M
T/O0.00
T/O Rate0.00%
Tradable Shares1.26M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
LIMINAL BIOSCIENCES ANNOUNCES COMPLETION OF THE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP
Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.